Use of analgesics in intentional drug overdose presentations to hospital before and after the withdrawal of distalgesic from the Irish market
© Corcoran et al; licensee BioMed Central Ltd. 2010
Received: 26 June 2009
Accepted: 18 March 2010
Published: 18 March 2010
Distalgesic, the prescription-only analgesic compound of paracetamol (325 mg) and dextropropoxyphene (32.5 mg) known as co-proxamol in the UK, was withdrawn from the Irish market as of January 2006. This study aimed to evaluate the impact of the withdrawal of distalgesic in terms of intentional drug overdose (IDO) presentations to hospital emergency departments (EDs) nationally.
A total of 42,849 IDO presentations to 37 of the 40 hospitals EDs operating in Ireland in 2003-2008 were recorded according to standardised procedures. Data on sales of paracetamol-containing drugs to retail pharmacies for the period 1998-2008 were obtained from IMS Health.
The withdrawal of distalgesic from the Irish market resulted in an immediate reduction in sales to retail pharmacies from 40 million tablets in 2005 to 500,000 tablets in 2006 while there was a 48% increase in sales of other prescription compound analgesics. The rate of IDO presentations to hospital involving distalgesic in 2006-2008 was 84% lower than in the three years before it was withdrawn (10.0 per 100,000). There was a 44% increase in the rate of IDO presentations involving other prescription compound analgesics but the magnitude of this rate increase was five times smaller than the magnitude of the decrease in distalgesic-related IDO presentations. There was a decreasing trend in the rate of presentations involving any paracetamol-containing drug that began in the years before the distalgesic withdrawal.
The withdrawal of distalgesic has had positive benefits in terms of IDO presentations to hospital in Ireland and provides evidence supporting the restriction of availability of means as a prevention strategy for suicidal behaviour.
Distalgesic (known as co-proxamol in the UK) is a prescription-only analgesic compound of paracetamol (325 mg) and dextropropoxyphene (32.5 mg). Evidence of the dangers of distalgesic in overdose began with a case-series study in Northern Ireland over 30 years ago  and culminated with a study that showed that the drug was the second most commonly used drug in overdose suicides in England and Wales, accounting for 5% of all suicides and with a higher risk of fatal outcome in overdose acts than other commonly used medicines . Death from distalgesic overdose may occur rapidly, even with a relatively low dose, and lethality is increased by use of alcohol and other central nervous system depressants. As a consequence, the majority of overdose deaths occur before hospital treatment can be received . After extensive review of the risks and benefit, the drug was withdrawn from the UK market over a three-year period, 2005-2007. Distalgesic was withdrawn from the Irish market as of January 2006.
The efficacy of various suicide prevention strategies to reduce the risk of suicide involving distalgesic has been evaluated, including educational strategies for doctors, restricting the number of prescribed tablets, restrictions on prescribing and complete withdrawal . So far, restricting availability of distalgesic has produced positive results in the UK, Scandinavia and Australia [4–8].
This study aimed to evaluate the impact of the withdrawal of distalgesic from the Irish market in terms of intentional drug overdose (IDO) presentations to hospital emergency departments (EDs) nationally. Specifically, we compared the rate of presentations to hospital of IDO acts involving distalgesic before (2003-2005) and after (2006-2008) its withdrawal, tested for evidence of substitution whereby there was a change in the rate of overdose presentations involving other paracetamol-containing drugs and examined whether there was a change in the number of tablets taken in overdose presentations involving distalgesic. We also examined changes in sales to retail pharmacies of paracetamol-containing analgesics.
The National Registry of Deliberate Self Harm collects data from all hospital emergency departments (EDs) in Ireland using an internationally-recognised definition that includes all non-fatal intentional drug overdose (IDO) acts . Registry data are collected by trained data registration officers who operate independently of the hospitals and follow standard operating procedures. Quality control measures include regular team meetings to reinforce the standardised application of case-definition and ascertainment criteria as well as cross-checking exercises which have shown high levels of agreement and reliability across registration officers. A minimal dataset is collected, described in detail in the Registry's annual reports . The dataset includes the age, gender and area of residence of the patient, data regarding the nature of the self-harming behaviour and whether the patient was hospitalised. If multiple IDO presentations are made by the same individual, all are recorded by the Registry. Ethical approval for the Registry was granted by the National Ethics Committee of the Faculty of Public Health Medicine as well as by local ethics committees.
Population data from the 2006 national census and annual population estimates for 2003, 2004, 2005, 2007 and 2008 (disaggregated by sex and age group) were obtained from the website of the Irish Central Statistics Office (CSO; http://www.cso.ie/). IMS Health supplied data on wholesale sales of paracetamol-containing drugs to retail pharmacies in Ireland for the period 1998-2008.
Of the 40 hospital EDs operating in Ireland in 2003-2008, the Registry obtained data from 37 hospitals in 2003, 38 hospitals in 2004-2005 and all 40 hospitals in 2006-2008. Statistical analysis was limited to the data collected from the 37 hospitals that contributed to the Registry for the complete study period (2003-2008). These hospitals accounted for 86.5% of all Registry-recorded IDO presentations in 2006-2008. This proportion was used to derive a weighting (100/86.5 = 1.16) that was applied to the data of the 37 hospitals for all study years and these weighted data were used to calculate national presentation rates. Total, male and female rates of IDO presentations to hospital per 100,000 population were age-standardised using the European standard population . Five year age groups (0-4, 5-9, ..., 80-84 and 85+) were used for the age-standardisation but when the data were more limited broader age groups were used (0-14, 15-34, 35-54, 55+). Assuming that the number of presentations (x) followed a Poisson distribution, 95% confidence intervals (CIs) for the rates were calculated using the Normal approximation, i.e. confidence interval = (x +/- 2*√x) * 100,000/population.
Data analysis was carried out relating to all IDO presentations, presentations involving any paracetamol-containing drug and presentations involving distalgesic. We also examined presentations involving the other common, paracetamol compound, prescription-only, moderate-severe painkillers that were available in the country across the study period (Kapake, Paramol, Solpadol, Syndol and Tylex; referred to as 'other prescription compound analgesics' in the paper) and presentations involving solpadeine, by far the most common over-the-counter paracetamol compound analgesic available only from pharmacies.
Chi-square tests were used to assess whether the proportion of IDO presentations to hospital involving distalgesic varied by sex, age and year. Poisson regression analysis was used to assess rate differences by sex and year and changes between the three pre-withdrawal years and the three post-withdrawal years collectively and separately (i.e. 2003-2005 vs. 2006-2008 and 2003-2005 vs. 2006, 2007, 2008). The number of distalgesic tablets taken was recorded in 84% of the IDO presentations involving the drug. Because of its skewed distribution, the number of tablets was summarised by the median and interquartile range. The non-parametric Mann-Whitney test was used to assess variation in the number of tablets taken between two groups and the Kruskal-Wallis test was used to compare more than two groups.
The statistical analysis was carried out using SPSS version 16.0 (SPSS Inc., Illinois, USA) except for the Poisson regression analyses, which were carried out using Stata version 6.0 (StataCorp, Texas, USA).
In 2003-2008, there were 42,849 recorded intentional drug overdose (IDO) presentations to the 37 hospital EDs that contributed fully to the Registry during these six years (annual mean (range): 7,142 (6,642-7,692)). Women accounted for 61.2% of all IDO presentations, a proportion that did not vary by year (Chi-square = 5.33, df = 5, p = 0.139). In 2,050 (4.8%) of the IDO presentations, it was not known what drugs were taken. The total, male and female annual rates of IDO presentations to hospital EDs were 188.4 (95% CI = 186.6-190.1), 143.5 (95% CI = 141.3-145.7) and 234.3 (95% CI = 231.5-237.0) per 100,000 population, respectively. Female sex was associated with a 60% higher rate of IDO presentations after adjustment for age (IRR = 1.60, 95% CI = 1.57-1.63). At least one paracetamol-containing drug was involved in 13,066 (30.5%) of the IDO presentations. The total, male and female annual rates of IDO presentations to hospital involving paracetamol were 57.0 (95% CI = 56.0-57.9), 35.4 (95% CI = 34.3-36.5) and 79.1 (95% CI = 77.5-80.7) per 100,000 population, respectively. After adjustment for age, female sex was associated with a more than doubling of the rate of paracetamol-related IDO presentations (IRR = 2.21, 95% CI = 2.13-2.28).
Intentional drug overdose presentations to hospital in Ireland involving distalgesic
% of all IDO presentations
% of paracetamol-related IDO presentations
Use of analgesics in intentional drug overdose presentations to hospital in Ireland before and after the withdrawal of distalgesic
Drug involved in presentations
Other prescription compound analgesics
The withdrawal of distalgesic from the Irish market in January 2006 resulted in an immediate reduction in sales to retail pharmacies. The rate of intentional drug overdose (IDO) presentations to hospital involving distalgesic in 2006-2008 was 84% lower than in the three years pre-withdrawal. The magnitude of the impact of the withdrawal was greater than the effects of the withdrawal of distalgesic (co-proxamol) on drug-related suicide mortality in Scotland  and in England and Wales  where the withdrawal was phased over the three years 2005-2007. Scottish poisoning deaths involving co-proxamol as the sole agent were 50% lower in 2005-2006 than in 2000-2004 . In England and Wales, the three withdrawal years saw a decrease of 59% in the prescribing of co-proxamol and a 62% decrease in suicide deaths compared to 1998-2004 . In Sweden, restrictions on the prescribing of drugs containing dextropropoxyphene were implemented in 2000-2002 and these were associated with a 66% decrease in sales, a 62% decrease in the number of dextropropoxyphene poisoning deaths and a 28% decrease in the number of dextropropoxyphene inquiries to the Swedish Poisons Information Centre .
In Ireland, the 48% jump in sales of the other prescription compound analgesics (Kapake, Paramol, Solpadol, Syndol and Tylex) between 2005 and 2006 was likely to have been due to doctors prescribing these drugs as alternatives to the withdrawn distalgesic. The 11% increase in sales of solpadeine and 22% increase in sales of other paracetamol-containing medicines may have been partially related to the withdrawal of distalgesic. However, these increases were not greatly out of line with the annual increases in the sales of these drugs in the years before distalgesic was withdrawn. There was also evidence of a degree of substitution in respect of IDO presentations to hospital. The increased availability of the other prescription compound analgesics resulted in a significant increase in the rate of IDO presentations to hospital involving these drugs. However, the magnitude of the decrease in distalgesic-related IDO presentations was about five times greater than the magnitude of the increase in IDO presentations involving the other prescription compound analgesics. Recent UK studies of the impact of distalgesic (co-proxamol) withdrawal on suicide mortality found little or no evidence of substitution [5, 7]. The total rate of IDO presentations to hospital and the rate of paracetamol-related presentations were decreasing in the three years before the withdrawal of distalgesic and continued to do so until 2008.
We found evidence of a time lag in the effect of the withdrawal of distalgesic on IDO presentations. Sales of the drug to retail pharmacies decreased by 99% in 2006 whereas the rate of distalgesic-related IDO presentations was 72%, 84% and 94% lower in 2006, 2007 and 2008, respectively. The evidence of a reduction in the number of distalgesic tablets taken in overdose acts was very limited and only seemed apparent in 2008 and even then half of those presentations involved more than 15 tablets. These findings may reflect the availability of distalgesic from already-filled prescriptions and a gradual reduction in household stocks. The Dispose of Unused Medicines Properly (DUMP) campaign is a separate initiative also aimed at restricting access to means of suicidal behaviour http://www.imt.ie/opinion/2009/05/dumping_drugs_saves_lives.html. Carried out in a number of areas across Ireland, the DUMP campaign called on the general public to bring medicines that were out-of-date or no longer in use to participating pharmacies where they were collected and subsequently destroyed. The campaign may have accelerated the disposal of distalgesic from the homes of patients. However, it may have more effective had the DUMP campaign been adopted nationally and promoted in conjunction with the withdrawal of distalgesic. In relation to future preventive initiatives, there is a need for greater awareness and promotion of existing initiatives that have the potential to be complimentary.
The study had a number of strengths and limitations. We were able to examine data relating to IDO presentations to the vast majority, though not all, of the hospitals in Ireland. In line with recommendations for the evaluation of initiatives restricting access to means of suicidal behaviour , we examined data from the three years before and the three years after the withdrawal of distalgesic. We examined sales to retail pharmacy data to assess changes in the availability of the relevant drugs. However, we did not include sales to hospital pharmacies and therefore our figures underestimate total sales somewhat. Changes in presentation rates and the number of tablets taken were examined for IDO presentations involving distalgesic and other relevant drugs. Substitution to other methods of self-poisoning or self harm was not examined. Legislation restricting pack-sizes of paracetamol-only drugs was implemented during the study period  which may explain the decrease in the rate of paracetamol-related IDO presentations observed in the study period. The study was confined to IDO presentations to hospital emergency departments and therefore excluded untreated acts and those managed by general practitioners. It would also have been of interest to have examined suicide data. However, at the time of the study, Irish suicide data were available only up to 2006 and the data could not distinguish deaths involving distalgesic from those involving other analgesics.
The withdrawal of distalgesic from the Irish market resulted in a marked reduction in the rate of IDO presentations to hospital involving the drug. The smaller increase in IDO presentations involving other prescription compound analgesics constituted evidence of some substitution. However, the withdrawal of distalgesic in Ireland can be considered a positive measure in the prevention of non-fatal suicidal behaviour, which is likely also to have an effect on suicide.
We would like to acknowledge the support of the UK Medical and Healthcare products Regulatory Agency (MHRA) and to thank Dr Sarah Fitzgibbon for her advice and comments and IMS Health for supplying the data on sales of paracetamol-containing drugs to retail pharmacies in Ireland. We would like to thank all who contribute to the Irish National Registry of Deliberate Self Harm, in particular Ms Eileen Williamson, Executive Director and the data registration officers. The Registry is funded by the Irish Health Service Executive's National Office for Suicide Prevention.
- Carson DJ: Fatal dextropropoxyphene poisoning in Northern Ireland. Review of 30 cases. Lancet. 1977, 1 (8017): 894-897. 10.1016/S0140-6736(77)91212-0.View ArticlePubMedGoogle Scholar
- Hawton K, Simkin S, Deeks J: Co-proxamol and suicide: a study of national mortality statistics and local non-fatal self poisonings. Bmj. 2003, 326 (7397): 1006-1008. 10.1136/bmj.326.7397.1006.View ArticlePubMedPubMed CentralGoogle Scholar
- Simkin S, Hawton K, Sutton L, Gunnell D, Bennewith O, Kapur N: Co-proxamol and suicide: preventing the continuing toll of overdose deaths. Q J Med. 2005, 98 (3): 159-170.View ArticleGoogle Scholar
- Hardwicke C, Holt L, James R, Smith AJ: Trends in self-poisoning with drugs in Newcastle, New South Wales, 1980-1982. Med J Aust. 1986, 144 (9): 453-454.PubMedGoogle Scholar
- Hawton K, Bergen H, Simkin S, Brock A, Griffiths C, Romeri E, Kapur N, Gunnell D: Impact of withdrawal of co-proxamol: Time series analysis of prescribing and drug poisoning deaths in England and Wales. Bmj. 2009, 338: b2270-10.1136/bmj.b2270.View ArticlePubMedPubMed CentralGoogle Scholar
- Jonasson U, Jonasson B: Restrictions on the prescribing of dextropropoxyphene (DXP) - effects on sales and cases of fatal poisoning. Report for the Swedish National Board of Forensic Medicine and Medical Products Agency. 2004, [http://www.rmv.se/fileadmin/RMVFiles/pdf/publicerat/dxp-report.pdf]Google Scholar
- Sandilands EA, Bateman DN: Co-proxamol withdrawal has reduced suicide from drugs in Scotland. Br J Clin Pharmacol. 2008, 66 (2): 290-293. 10.1111/j.1365-2125.2008.03206.x.View ArticlePubMedPubMed CentralGoogle Scholar
- Segest E, Harris CN, Bay H: Dextropropoxyphene deaths in Denmark from the health authority point of view. Med Law. 1993, 12 (1-2): 141-151.PubMedGoogle Scholar
- Platt S, Bille-Brahe U, Kerkhof A, Schmidtke A, Bjerke T, Crepet P, De Leo D, Haring C, Lonnqvist J, Michel K: Parasuicide in Europe: the WHO/EURO multicentre study on parasuicide. I. Introduction and preliminary analysis for 1989. Acta Psychiatr Scand. 1992, 85 (2): 97-104. 10.1111/j.1600-0447.1992.tb01451.x.View ArticlePubMedGoogle Scholar
- National Suicide Research Foundation: National Parasuicide Registry Ireland Annual Report 2006-2007. 2008, Cork: National Suicide Research Foundation, [http://www.nsrf.ie/npr2006_07.htm]Google Scholar
- Waterhouse J, Muir C, Correa P, Powell J: Cancer incidence in five continents. 1976, Lyon: IARCGoogle Scholar
- Hawton K: Restricting access to methods of suicide: Rationale and evaluation of this approach to suicide prevention. Crisis. 2007, 28 (Suppl 1): 4-9.View ArticleGoogle Scholar
- Statutory Instrument (SI 150): Medicinal Products (Control of Paracetamol) Regulations. Dublin. 2001Google Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6904/10/6/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.